


<p style="text-align: center;">PEPTIDE-DRUG CONJUGATES: A new promising class of molecules to fight cancer and microbial infections</p>	
Datum i vrijeme:	Utorak, 23. travnja 2024., 10.00 – 10:30,
Vrsta aktivnosti:	Kratka crtica
Lokacija:	Fakulteta Biotehnologije i razvoje lijekova, predavaonica O-268, 2. kat
Mentor i voditelj:	doc. dr. sc. Toni Todorovski

Sažetak:

According to the World Health Organization (WHO), **antimicrobial resistance (AMR)** is one of the top ten global public health threats that humanity is facing, while in 2019 **cancer disease** became the leading cause of death in the industrialized countries (in Croatia second leading cause). Over the last two decades, **peptide–drug conjugates (PDCs)** have emerged as very important class of prodrugs to tackle various infectious diseases and cancers. PDC therapeutics combine one or more small drug molecules conjugated, most often, to a cell-penetrating peptide (CPP) either directly or through a biodegradable linker. This integration of two bioactive elements into a single entity often provides novel functionalities and improved bioavailability to treat conditions where conventional drugs are ineffective. In this talk we will highlight the **recent advancements** and current research hot-spots in the field of PDC therapeutics against microbial infections and cancers.

Biografija:

Porijeklom Makedonac, Toni Todorovski je kemičar koji se obrazovao na Sveučilištu u Skopju, Sveučilištu u Lajpcigu te Sveučilištu Pompeu Fabra u Barcelonu. Peptidnom medicinskom kemijom se bavi od 2008. godine, a od 2023. godine je voditelj vlastite istraživačke grupe na Fakultetu biotehnologije i razvoja lijekova, Sveučilišta u Rijeci.

